Caisse DE Depot ET Placement DU Quebec Boosts Stake in Mylan NV (MYL)
Caisse DE Depot ET Placement DU Quebec grew its position in shares of Mylan NV (NASDAQ:MYL) by 19.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 232,920 shares of the company’s stock after acquiring an additional 37,800 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Mylan were worth $8,418,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Analyst IMS Investment Management Services Ltd. bought a new position in shares of Mylan during the 1st quarter valued at approximately $117,000. First Mercantile Trust Co. bought a new position in shares of Mylan during the 2nd quarter valued at approximately $121,000. CENTRAL TRUST Co boosted its position in shares of Mylan by 1,057.8% during the 2nd quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock valued at $188,000 after acquiring an additional 4,760 shares during the last quarter. FTB Advisors Inc. purchased a new stake in Mylan during the 2nd quarter valued at $188,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in Mylan during the 2nd quarter valued at $218,000. Hedge funds and other institutional investors own 82.41% of the company’s stock.
MYL stock opened at $38.24 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.77 and a current ratio of 1.29. Mylan NV has a twelve month low of $30.69 and a twelve month high of $47.82. The firm has a market capitalization of $20.07 billion, a price-to-earnings ratio of 8.39, a price-to-earnings-growth ratio of 1.23 and a beta of 1.44.
Several research firms recently weighed in on MYL. Guggenheim restated a “buy” rating and set a $59.00 price target on shares of Mylan in a report on Thursday, June 14th. ValuEngine upgraded Mylan from a “sell” rating to a “hold” rating in a report on Wednesday, June 13th. BidaskClub upgraded Mylan from a “hold” rating to a “buy” rating in a report on Wednesday, June 13th. JPMorgan Chase & Co. set a $53.00 price target on Mylan and gave the company a “buy” rating in a report on Wednesday, May 23rd. Finally, Wells Fargo & Co set a $41.00 price target on Mylan and gave the company a “hold” rating in a report on Wednesday, August 8th. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $47.37.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: The Role of a Fiduciary and Individual Investors
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.